SOM Biotech and the Vall d’Hebron Research Institute (VHIR) have completed a Phase IIa Clinical Study with compound SOM0226, a repositioned drug for the treatment of transthyretin amyloidosis. Results show excellent drug efficacy and safety in patients for the treatment of this rare disease.
PRESS RELEASE (Spanish)

PRESS RELEASE (Catalan)

PRESS RELEASE (English)

SUBCRIBE TO OUR NEWSLETTER

    Name*
    Email*


    I confirm that by completing this form I have used only personal data about myself and that they are true and up-to-date.
    SOM INNOVATION BIOTECH, S.A. is responsible for the processing of my personal data to manage the newsletter service requested through the form, as well as to track the receipt of these through tracking technologies. The Privacy Policy tells me how I can exercise my rights of access, rectification, deletion, limitation, portability and opposition.